4 Stocks Make It On Today's Healthcare & Biotech Stock Watchlist
Powered by HealthTechMovers.com
We added 4 stocks to our Healthcare & Biotech Stock Watchlist today because they are receiving Bullish Sentiment from investors and financial bloggers.
In addition, they are generating positive media buzz and/or have insider trading signals which came to our attention. This list below is subject to change on a daily basis, so please be sure you subscribe to our email newsletter.
TransMedics Group, Inc., TMDX
Summary: TransMedics Inc. is a commercial-stage medical technology company. It is engaged in transforming organ transplant therapy for end-stage organ failure patients. The company offers Organ Care System, an integrated, compact, portable preservation technology which addresses unmet need for organs for transplantation. TransMedics Inc. is headquartered in Andover, Massachusetts.
- Last Price: $91.82
- Price Change: $-2.13, -2.27%
- Yearly Gain: 38.64%
- Market Cap: $3.00B
- P/E Ratio: -119.25
Here are 3rd party ratings for TMDX:
- TipRanks.com: Buy
- TradingView.com:
- Yahoo! Finance: Bullish Short-Term Outlook
- Barchart.com: Strong buy
- Zacks.com: Strong Buy, Top 39% (99 out of 252)
What is the sentiment on the street regarding TransMedics Group, Inc. ? (Current ratings compiled by TipRanks.com)
- News Sentiment: Bullish
- Blogger Consensus:
- Media Buzz: Strong Buy
- Insider Signal: Balanced
- Investor Sentiment: Positive
- Hedge Fund signal: High Risk
If you are interested in TMDX or any stocks within the Healthcare sector, you might want to click here and check out this report. The stock market is extremely volatile, and you need to do your own research on TMDX before you decide to make any investment.
Click here for chart >>
Janux Therapeutics, Inc., JANX
Summary: Janux Therapeutics Inc. is a biopharmaceutical company. It involved in developing novel T cell engager immunotherapies. Janux Therapeutics Inc. is based in LA JOLLA, Calif.
- Last Price: $52.65
- Price Change: $2.65, 5.30%
- Yearly Gain: 259.63%
- Market Cap: $2.72B
- P/E Ratio: -39.89
Here are 3rd party ratings for JANX:
- TipRanks.com: Buy
- TradingView.com:
- Yahoo! Finance: Bullish Short-Term Outlook
- Barchart.com: Strong buy
- Zacks.com: Buy, Top 37% (92 out of 252)
What is the sentiment on the street regarding Janux Therapeutics, Inc. ? (Current ratings compiled by TipRanks.com)
- News Sentiment: Bullish
- Blogger Consensus:
- Media Buzz: Sell
- Insider Signal: Balanced
- Investor Sentiment: Positive
- Hedge Fund signal: Medium Risk
If you are interested in JANX or any stocks within the Healthcare sector, you might want to click here and check out this report. The stock market is extremely volatile, and you need to do your own research on JANX before you decide to make any investment.
Click here for chart >>
Celldex Therapeutics, Inc., CLDX
Summary: CELLDEX THERAPEUTICS is an integrated biopharmaceutical company that applies its comprehensive Precision Targeted Immunotherapy Platform to generate a pipeline of candidates to treat cancer and other difficult-to-treat diseases. Celldex's immunotherapy platform includes a complementary portfolio of monoclonal antibodies, antibody-targeted vaccines and immunomodulators to create novel disease-specific drug candidates.
- Last Price: $39.25
- Price Change: $-1.62, -3.96%
- Yearly Gain: 29.58%
- Market Cap: $2.53B
- P/E Ratio: -13.44
Here are 3rd party ratings for CLDX:
- TipRanks.com: Buy
- TradingView.com:
- Yahoo! Finance: Bullish Short-Term Outlook
- Barchart.com: buy
- Zacks.com: Buy, Top 37% (92 out of 252)
What is the sentiment on the street regarding Celldex Therapeutics, Inc. ? (Current ratings compiled by TipRanks.com)
- News Sentiment: Bullish
- Blogger Consensus:
- Media Buzz: Sell
- Insider Signal: Balanced
- Investor Sentiment: Positive
- Hedge Fund signal: Medium Risk
If you are interested in CLDX or any stocks within the Healthcare sector, you might want to click here and check out this report. The stock market is extremely volatile, and you need to do your own research on CLDX before you decide to make any investment.
Click here for chart >>
CorMedix Inc., CRMD
Summary: CorMedix Inc. is a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases. The Company is focused on developing its lead product Defencath (TM), a novel, antibacterial and antifungal solution designed to prevent costly and life-threatening bloodstream infections associated with the use of central venous catheters in patients undergoing chronic hemodialysis. Defencath has been designated by FDA as Fast Track and as a Qualified Infectious Disease Product, which provides an additional five years of marketing exclusivity, which will be added to the five years granted to a New Chemical Entity upon approval of the NDA. CorMedix also intends to develop Defencath as a catheter lock solution for use in oncology and total parenteral nutrition patients. It is leveraging its taurolidine technology to develop a pipeline of antimicrobial medical devices, with programs in surgical sutures and meshes, and topical hydrog
- Last Price: $5.84
- Price Change: $-0.55, -8.61%
- Yearly Gain: 10.82%
- Market Cap: $320.10M
- P/E Ratio: -6.87
Here are 3rd party ratings for CRMD:
- TipRanks.com: Buy
- TradingView.com:
- Yahoo! Finance: Bullish Short-Term Outlook
- Barchart.com: Strong buy
- Zacks.com: Buy, Top 37% (92 out of 252)
What is the sentiment on the street regarding CorMedix Inc. ? (Current ratings compiled by TipRanks.com)
- News Sentiment: Bullish
- Blogger Consensus:
- Media Buzz: Neutral
- Insider Signal: Buying
- Investor Sentiment: Positive
- Hedge Fund signal: Medium Risk
If you are interested in CRMD or any stocks within the Healthcare sector, you might want to click here and check out this report. The stock market is extremely volatile, and you need to do your own research on CRMD before you decide to make any investment.
Click here for chart >>
Thanks for reading!